Cmin

is a term used in pharmacokinetics for the minimum blood plasma concentration reached by a drug during a dosing interval, which is the time interval between administration of two doses. This definition is slightly different from , the concentration immediately prior to administration of the next dose. is the opposite of , the maximum concentration that the drug reaches. must be above certain thresholds, such as the minimum inhibitory concentration (MIC), to achieve a therapeutic effect. In most cases is directly measurable. At steady state the minimum plasma concentration can also be calculated using the following equation: C_{min} = \frac{SFDk_a}{V_d(k_a-k_e)} \times \left( \frac{e^{-k_e\tau}}{1-e^{-k_e\tau}}-\frac{e^{-k_a\tau}}{1-e^{-k_a\tau}} \right) : = Salt factor : = Bioavailability : = Dose : = Elimination rate constant : = Absorption rate constant : = Volume of distribution : = Dosing interval is also an important parameter in bioavailability and bioequivalence studies, it is part of the pharmacokinetic information recommended for submission of investigational new drug applications.

is a term used in pharmacokinetics for the minimum blood plasma concentration reached by a drug during a dosing interval, which is the time interval between administration of two doses. This definition is slightly different from , the concentration immediately prior to administration of the next dose. is the opposite of , the maximum concentration that the drug reaches. must be above certain thresholds, such as the minimum inhibitory concentration (MIC), to achieve a therapeutic effect. In most cases is directly measurable. At steady state the minimum plasma concentration can also be calculated using the following equation: C_{min} = \frac{SFDk_a}{V_d(k_a-k_e)} \times \left( \frac{e^{-k_e\tau}}{1-e^{-k_e\tau}}-\frac{e^{-k_a\tau}}{1-e^{-k_a\tau}} \right) = Salt factor = Bioavailability = Dose = Elimination rate constant = Absorption rate constant = Volume of distribution = Dosing interval is also an important parameter in bioavailability and bioequivalence studies, it is part of the pharmacokinetic information recommended for submission of investigational new drug applications.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1355374392 under CC BY-SA 4.0; modifications have been made.